Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Apr 14;10(4):40.
doi: 10.1038/s41408-020-0307-4.

Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents

Roberto Mina  1   2 , Nisha S Joseph  3 , Francesca Gay  4 , Efstathios Kastritis  5 , Maria Teresa Petrucci  6 , Jonathan L Kaufman  3 , Vittorio Montefusco  7 , Maria Gavriatopoulou  5 , Francesca Patriarca  8 , Paola Omedé  4 , Lawrence H Boise  3 , Maria Roussou  5 , Nicola Giuliani  9 , Stefania Oliva  4 , Massimo Offidani  10 , Angelo Belotti  11 , David L Jaye  12 , Lorenzo De Paoli  13 , Evangelos Terpos  5 , Sagar Lonial  3 , Mario Boccadoro  4 , Ajay K Nooka  3 , Meletios A Dimopoulos  5
Affiliations

Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents

Roberto Mina et al. Blood Cancer J. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

R.M. has received honoraria from Amgen, Celgene, Takeda, and Janssen; has served on the advisory boards for Janssen. F.G. has received honoraria from Amgen, Celgene, Janssen, Takeda, and Bristol-Myers Squibb; has served on the advisory boards for Amgen, Celgene, Janssen, Takeda, Bristol-Myers Squibb, Roche, AbbVie, Adaptive, and Seattle Genetics. E.K. has received honoraria by Amgen, Genesis Pharma, Janssen, Takeda, and research grants from Amgen and Janssen. M.T.P. has received honoraria from and served on the advisory boards for Amgen, Bristol-Myers Squibb, Celgene, Janssen, and Takeda. J.L.K. has consulted for Roche, AbbVie, Janssen, BMS, Takeda, and Karyopharm. V.M. has received honoraria from Amgen, Celgene, Bristol-Myers-Squibb, and Janssen. F.P.: advisory role: Janssen, Celgene, MSD Italy; travel, accomodations, expenses: Celgene, Jazz, Medac. P.O. has served on the advisory board for Janssen. L.H.B. has received honoraria from AstraZeneca and undertaken consultancy for AbbVie and AstraZeneca. N.G. has received honoraria from Bristol-Myers Squibb, Celgene, Janssen; has served on the advisory boards for Amgen, Celgene, Takeda, Janssen; has received research funding from Celgene, Janssen; has received sponsorship for clinical trials from GlaxoSmithKline, Janssen, and Takeda. S.O. has received honoraria from Amgen, Celgene, and Janssen; has served on the advisory boards for Adaptive Biotechnologies, Janssen, Amgen, and Takeda. M.O. has received honoraria from Amgen, BMS, Celgene, Janssen, Takeda, and served on the advisory boards for Amgen, BMS, Celgene, Janssen, and Takeda. A.B. has served on the advisory boards for Amgen, Celgene, and Janssen. L.D.P. has received honoraria from and served on the advisory boards for Amgen, Janssen, Celgene, and Shire. E.T. has received honoraria from Amgen, Celgene, Janssen, Takeda, Bristol-Myers Squibb; has received research support from Amgen, Celgene, and Janssen. S.L. has consulted for Takeda, Celgene, Novartis, Janssen, GSK, Bristol-Myers Squibb, and Merck. M.B. has received honoraria from Sanofi, Celgene, Amgen, Janssen, Novartis, AbbVie, and Bristol-Myers Squibb; has received research funding from Celgene, Janssen, Amgen, Bristol-Myers Squibb, Mundipharma, Novartis, and Sanofi. A.K.N. has served on the advisory board for GSK, Spectrum, Celgene, Amgen, Novartis Pharmaceuticals, Adaptive Biotechnologies; has received honoraria from Bristol-Myers Squibb and Janssen Pharmaceuticals. M.A.D. has received honoraria from participation in advisory boards for Amgen, Celgene, Janssen, Bristol-Myers Squibb, and Takeda. The remaining authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1. Time-to-event analysis.
Kaplan–Meier progression-free survival (a PFS progression-free survival) and overall survival (b OS overall survival) curves in t(14;16)-positive patients. Blue curve: t(14;16)-positive patients overall; orange curve: t(14;16)-positive patients with additional CAs chromosomal abnormalities [del(17p) and/or del(13q) and/or amp(1q)]; green curve: t(14;16)-positive patients without additional CAs.
See this image and copyright information in PMC

References

    1. Fonseca R, et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood. 2003;101:4569–4575. doi: 10.1182/blood-2002-10-3017. - DOI - PubMed
    1. Boyd KD, et al. A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial. Leukemia. 2012;26:349–355. doi: 10.1038/leu.2011.204. - DOI - PMC - PubMed
    1. Lakshman A, et al. Natural history of t(11;14) multiple myeloma. Leukemia. 2018;32:131–138. doi: 10.1038/leu.2017.204. - DOI - PubMed
    1. Chng WJ, et al. IMWG consensus on risk stratification in multiple myeloma. Leukemia. 2014;28:269–277. doi: 10.1038/leu.2013.247. - DOI - PubMed
    1. Palumbo A, et al. Revised international staging system for multiple myeloma: a report from international myeloma working group. J. Clin. Oncol. 2015;33:2863–2869. doi: 10.1200/JCO.2015.61.2267. - DOI - PMC - PubMed